Sihuan Pharmaceutical Holdings Group Ltd.: Xuanzhu Biopharm Added to Hang Seng Composite Index

Key Points for Investors

• Xuanzhu Biopharm Included as Constituent Stock:
  Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 0460) announced that its non-wholly-owned subsidiary, Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu Biopharm”, stock code: 2575), has been included as a constituent stock in the Hang Seng Composite Index. This inclusion is based on the quarterly review results of the Hang Seng Family of Indexes for the period ended 31 December 2025, released on 13 February 2026. The adjustment will take effect on 9 March 2026.
• Significance of Inclusion:
  The Hang Seng Composite Index is a comprehensive benchmark for the Hong Kong stock market, covering listed companies on the Main Board with a cumulative market capitalization ranking among the top 95%. Inclusion in this index not only elevates Xuanzhu Biopharm’s profile but also positions it for eligibility in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect trading programs. This opens doors for investment from Mainland China, potentially increasing demand for Xuanzhu Biopharm shares.
• Market Recognition and Growth Potential:
  Being selected for the Hang Seng Composite Index reflects investors’ recognition of Xuanzhu Biopharm’s value and growth prospects. It also affirms Sihuan Pharmaceutical’s innovative pharmaceutical strategy and underscores its achievements in developing novel drugs.
• Expected Positive Impacts:
  The Board anticipates that index inclusion will:
  • Enhance liquidity of Xuanzhu Biopharm shares
  • Expand its investor base and diversify shareholder structure
  • Increase reputation and investment value in the capital markets
  • Support long-term, stable development of Xuanzhu Biopharm
  • Deliver positive impacts for Sihuan Pharmaceutical Group as a whole
• Strategic Focus Going Forward:
  Sihuan Pharmaceutical remains committed to its innovation-driven development philosophy, focusing on two core segments: medical aesthetics and innovative pharmaceuticals, with a deeper global layout. The Group will fully support Xuanzhu Biopharm’s business development, promote delivery of innovative achievements and enhance commercialization capabilities.

Details About Xuanzhu Biopharm

• Xuanzhu Biopharm is Sihuan Pharmaceutical’s innovative drug subsidiary, rooted in China with a global perspective.
• The company focuses on major diseases such as digestive disorders, oncology, and non-alcoholic steatohepatitis.
• Xuanzhu Biopharm is dedicated to R&D, production, and commercialization of class 1 drugs with proprietary intellectual property rights.
• It boasts a first-class R&D team, with all core personnel possessing years of experience in new drug research and development.
• The company operates two R&D platforms: small molecule chemistry and large molecule biologics, supporting a diverse pipeline including small molecules, biopharmaceuticals, and antibody-drug conjugates (ADC).
• Xuanzhu Biopharm aims to address unmet major clinical needs and develop into a leading innovative pharmaceutical company with independent R&D, production, and sales capabilities.

About Sihuan Pharmaceutical Holdings Group Ltd.

• Founded in 2001 and listed on the Main Board of the Stock Exchange in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical leader.
• The company operates an independent and advanced R&D technology platform, a rich global product pipeline, strong product registration capabilities, efficient and cost-effective production, and a mature sales system.
• The strategic goal is a “two-wheel drive” between medical aesthetics and biopharmaceuticals, aiming to become a leading company in China in both sectors.

Important Considerations for Shareholders

• Potential Price Sensitivity: The inclusion of Xuanzhu Biopharm in the Hang Seng Composite Index is likely to be price-sensitive, as it increases visibility, potential trading activity, and access to new investors (including those from Mainland China via Stock Connect). These factors may positively impact both Xuanzhu Biopharm and Sihuan Pharmaceutical share values.
• Strategic Expansion: The Group’s continued focus on innovation and expansion in medical aesthetics and pharmaceuticals could drive further growth and market recognition.
• Management Commitment: The Board expressed gratitude to shareholders, investors, and partners for their support and reaffirmed dedication to innovation and shareholder value creation.

Board and Management

• Executive Directors: Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and CEO), Dr. Zhang Jionglong, Ms. Chen Yanling, Ms. Miao Guili
• Independent Non-Executive Directors: Mr. Tsang Wah Kwong, Dr. Zhu Xun, Mr. Wang Guan

Conclusion

The inclusion of Xuanzhu Biopharm in the Hang Seng Composite Index marks a significant milestone for Sihuan Pharmaceutical Holdings Group Ltd. This development not only increases visibility and accessibility for Xuanzhu Biopharm shares but also positions the company for further capital market growth and strategic expansion. Shareholders should monitor this news closely, as it may positively impact share values and signal continued progress in the Group’s innovation-driven strategy.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or an advertisement for any medicine, surgical appliance, treatment, or orally consumed product. Investors should conduct their own research and consult with professional advisors before making investment decisions.

View SIHUAN PHARM Historical chart here